S-DABO

Drug Profile

S-DABO

Latest Information Update: 29 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antiretrovirals; Contraceptives; Pyrimidines; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Contraception; HIV infections

Most Recent Events

  • 13 Apr 1999 Preclinical development for Contraception in USA (Vaginal)
  • 13 Apr 1999 New profile
  • 13 Apr 1999 Preclinical development for HIV infections treatment in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top